IP Attys Back Regeneron Over Inequitable Conduct Finding
Law360, New York (October 2, 2017, 6:04 PM EDT) -- Numerous intellectual property law organizations and lawyers are calling for the full Federal Circuit to review its panel decision affirming that a Regeneron Pharmaceuticals Inc. patent is unenforceable in part because of inequitable conduct of litigators during a later infringement case, arguing it could "seriously and negatively affect the course of patent prosecution."
The Intellectual Property Law Associations of both New York and Chicago, as well as the Washington Legal Foundation, the Biotechnology Innovation Organization and various practicing lawyers in the IP field all filed amicus briefs backing Regeneron's request for an en banc rehearing of a panel's split 2-1 decision...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!